Inhaled hydrogen therapy alleviates cognitive impairment in individuals with mild Alzheimer’s disease by optimising peripheral immune homeostasis: a clinical evaluation
Geng, Wenbo, Gao, Wenchan, Guo, Shuqiong, Shi, Lei · European Journal of Medical Research · 2026
Research-use notice
Independent study record
Each H2HUBB study page organizes source-linked research details for educational use. Interpretation should remain proportional to the study design, population, controls, and limitations.
H2HUBB TAKEAWAY
The study reports that This treatment was found to yield good compliance among patients with mild AD when used as an adjunctive treatment, indicating broad prospects for clinical adjunctive applications.
What the Researchers Studied
Source-reported study description: 80 patients with mild AD
What the Study Found
The authors reported: Receiver operating characteristic curve analysis revealed that the inhaled hydrogen therapy intervention partially improved the proportion of peripheral blood CD4 + T lymphocytes in patients.
The authors reported: Inhaled hydrogen therapy can effectively improve cognitive function and significantly reduce AD-related peripheral blood neuroimmunological markers in patients with mild AD.
What the Findings Mean
The authors concluded/reported: This treatment was found to yield good compliance among patients with mild AD when used as an adjunctive treatment, indicating broad prospects for clinical adjunctive applications.
Study Details
Publication type: human_clinical_study
Evidence source level: B_ABSTRACT
Original scholarly source: https://link.springer.com/article/10.1186/s40001-026-05106-0?error=cookies_not_supported&code=818a1a32-118a-416f-a5ad-9eac266e1566